Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1913 1
1922 1
1926 1
1950 1
1952 1
1973 1
1974 3
1975 1
1976 2
1977 2
1978 5
1979 5
1980 5
1981 3
1982 2
1983 4
1984 6
1985 11
1986 10
1987 12
1988 12
1989 15
1990 17
1991 22
1992 25
1993 20
1994 26
1995 24
1996 23
1997 24
1998 39
1999 35
2000 16
2001 20
2002 10
2003 22
2004 15
2005 22
2006 17
2007 26
2008 26
2009 33
2010 35
2011 31
2012 35
2013 50
2014 78
2015 96
2016 110
2017 102
2018 111
2019 97
2020 102
2021 113
2022 83
2023 100
2024 85

Text availability

Article attribute

Article type

Publication date

Search Results

1,673 results

Results by year

Filters applied: . Clear all
Page 1
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C, Lee JK, Klarenbeek S, Silverman IM, Annunziato S, Chan CS, Piersma SR, Eijkman T, Badoux M, Gogola E, Siteur B, Sprengers J, de Klein B, de Goeij-de Haas RR, Riedlinger GM, Ke H, Madison R, Drenth AP, van der Burg E, Schut E, Henneman L, van Miltenburg MH, Proost N, Zhen H, Wientjens E, de Bruijn R, de Ruiter JR, Boon U, de Korte-Grimmerink R, van Gerwen B, Féliz L, Abou-Alfa GK, Ross JS, van de Ven M, Rottenberg S, Cuppen E, Chessex AV, Ali SM, Burn TC, Jimenez CR, Ganesan S, Wessels LFA, Jonkers J. Zingg D, et al. Among authors: ross js. Nature. 2022 Aug;608(7923):609-617. doi: 10.1038/s41586-022-05066-5. Epub 2022 Aug 10. Nature. 2022. PMID: 35948633 Free PMC article. Clinical Trial.
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, Sylvester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe J, Ganzel C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block J, Héritier S, Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F, Taylor BS, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA, Abdel-Wahab O. Diamond EL, et al. Among authors: ross js. Cancer Discov. 2016 Feb;6(2):154-65. doi: 10.1158/2159-8290.CD-15-0913. Epub 2015 Nov 13. Cancer Discov. 2016. PMID: 26566875 Free PMC article.
Spine infection/inflammation.
DeSanto J, Ross JS. DeSanto J, et al. Among authors: ross js. Radiol Clin North Am. 2011 Jan;49(1):105-27. doi: 10.1016/j.rcl.2010.07.018. Radiol Clin North Am. 2011. PMID: 21111132 Review.
Immunotherapy in the Treatment of Localized Genitourinary Cancers.
Necchi A, Faltas BM, Slovin SF, Meeks JJ, Pal SK, Schwartz LH, Huang RSP, Li R, Manley B, Chahoud J, Ross JS, Spiess PE. Necchi A, et al. Among authors: ross js. JAMA Oncol. 2023 Oct 1;9(10):1447-1454. doi: 10.1001/jamaoncol.2023.2174. JAMA Oncol. 2023. PMID: 37561425 Free PMC article.
Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial.
Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, Costa de Padua T, Crupi E, Colombo R, Colecchia M, Lucianò R, Nocera L, Moschini M, Briganti A, Montorsi F, Necchi A. Basile G, et al. Among authors: ross js. Clin Cancer Res. 2022 Dec 1;28(23):5107-5114. doi: 10.1158/1078-0432.CCR-22-2158. Clin Cancer Res. 2022. PMID: 36190522 Clinical Trial.
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA. Frampton GM, et al. Among authors: ross js. Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13. Cancer Discov. 2015. PMID: 25971938
The high-field-strength curmudgeon.
Ross JS. Ross JS. AJNR Am J Neuroradiol. 2004 Feb;25(2):168-9. AJNR Am J Neuroradiol. 2004. PMID: 14970013 Free PMC article. No abstract available.
Next-generation pathology.
Ross JS. Ross JS. Am J Clin Pathol. 2011 May;135(5):663-5. doi: 10.1309/AJCPBMXETHAPAV1E. Am J Clin Pathol. 2011. PMID: 21502418 No abstract available.
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials.
Ciani O, Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS. Ciani O, et al. Among authors: ross js. EClinicalMedicine. 2023 Oct 17;65:102283. doi: 10.1016/j.eclinm.2023.102283. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 37877001 Free PMC article.
1,673 results